The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5(+) malignancy. Secondary aims were to assess clinical efficacy, immune effector function and optimal dose of CAR T cells. Three cohorts of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Thistlethwaite, Fiona C., Gilham, David E., Guest, Ryan D., Rothwell, Dominic G., Pillai, Manon, Burt, Deborah J., Byatte, Andrea J., Kirillova, Natalia, Valle, Juan W., Sharma, Surinder K., Chester, Kerry A., Westwood, Nigel B., Halford, Sarah E. R., Nabarro, Stephen, Wan, Susan, Austin, Eric, Hawkins, Robert E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645435/
https://www.ncbi.nlm.nih.gov/pubmed/28660319
http://dx.doi.org/10.1007/s00262-017-2034-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645435/
https://www.ncbi.nlm.nih.gov/pubmed/28660319
http://dx.doi.org/10.1007/s00262-017-2034-7

Ejemplares similares